- Alterity Therapeutics (ATH) has received a U.S. patent to trial treatments for neurodegenerative diseases, such as Alzheimer’s and Parkinson diseases
- The patent covers more than 150 types of treatments, which aim to readjust high iron levels in the brain related to neurodegenerative conditions
- The new patent will give the company 20 years of exclusivity and will support the expansion of Alterity’s drug development profile
- Currently, Alterity’s lead product, ATH434, is currently in clinical development and is showing positive signs
- Additionally, the company is looking at patent protection in other jurisdictions
- On the market today, Alterity is up 26.9 per cent and is trading for 3.3 cents per share
